Globenewswire
Search documents
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ramaco Resources, Inc. of Class Action Lawsuit and Upcoming Deadlines – METC
Globenewswire· 2026-02-24 21:41
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ramaco Resources, Inc. (“Ramaco” or the “Company”) (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Ramaco and certain of it ...
Kessler Topaz Meltzer & Check, LLP - NuScale Power Corporation Class Action Lawsuit: Investors Face April 20, 2026, Deadline
Globenewswire· 2026-02-24 21:34
Did you buy SMR Class A common stock between May 13, 2025, and November 6, 2025? Affected NuScale Power Corporation Investor Summary Who: NuScale Power Corporation (NYSE: SMR)What: Securities fraud class action lawsuit filedClass Period: May 13, 2025, through November 6, 2025Deadline to Seek Lead Plaintiff Status: April 20, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s commercialization strategy for its nuclear power generation projects and development.Investo ...
Phillips Edison & Company Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.750% Senior Unsecured Notes Due 2033
Globenewswire· 2026-02-24 21:34
CINCINNATI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the “Operating Partnership”), has priced a public offering of $350 million aggregate principal amount of 4.750% senior unsecured notes due 2033 (the “Notes”). The Notes ...
Sun Communities Reports 2025 Fourth Quarter and Full Year Results; Provides 2026 Guidance and Increases Quarterly Distribution Rate for 2026
Globenewswire· 2026-02-24 21:32
Net Income per Diluted Share of $0.99 for the Fourth Quarter and $10.84 for the Full Year of 2025 Core FFO per Share of $1.40 for the Fourth Quarter and $6.68 for the Full Year of 2025 North America Same Property NOI increased by 7.9% for the Fourth Quarter and 5.7% for the Full Year of 2025 Acquired 14 MH and RV Communities for $457.0 million and Distributed Over $1.5 Billion of Capital to Shareholders, Inclusive of Cash Distributions and Share Repurchases in 2025 Establishing Guid ...
ZYNEX LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zynex, Inc. and Encourages Investors to Contact the Firm
Globenewswire· 2026-02-24 21:31
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zynex (ZYXIQ) To Contact Him Directly To Discuss Their Options If you purchased or acquired Zynex securities between February 25, 2021 to December 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Br ...
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Globenewswire· 2026-02-24 21:30
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th A ...
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
Globenewswire· 2026-02-24 21:30
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creationCHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experi ...
Antalpha to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Globenewswire· 2026-02-24 21:30
SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market open on March 3, 2026. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on March 3, 2026 (or 9:00 P.M. Singapore Time on March 3, 2026) to discuss the financial resul ...
Inspired to Report Fourth Quarter and Full Year 2025 Results and Hold Conference Call on March 10
Globenewswire· 2026-02-24 21:30
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ("Inspired" or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 before the market opens on Tuesday, March 10, 2026. Inspired management will host a conference call and simultaneous webcast the same day at 8:30 a.m. ET / 12:30 p.m. in the UK to discuss the Company's resul ...
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Globenewswire· 2026-02-24 21:30
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (G ...